China Biotech Services Holdings Limited (HKG:8037)
Hong Kong · Delayed Price · Currency is HKD 0.7700
+0.0200 (2.67%)
At close: Mar 27, 2026
HKG:8037 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 73.5 | 70.51 | 211.99 | 1,852 | 623.76 | |
Revenue Growth (YoY) | 4.25% | -66.74% | -88.55% | 196.83% | -4.88% |
Cost of Revenue | 65.78 | 75.45 | 177.66 | 750.58 | 265.74 |
Gross Profit | 7.73 | -4.94 | 34.32 | 1,101 | 358.02 |
Selling, General & Admin | 66.44 | 143.22 | 152.95 | 254.88 | 168.81 |
Research & Development | 17.2 | - | - | - | - |
Other Operating Expenses | -23.59 | -2.53 | -0.64 | -0.72 | -0.32 |
Operating Expenses | 60.06 | 141.38 | 151.18 | 258.06 | 168.49 |
Operating Income | -52.33 | -146.32 | -116.86 | 842.9 | 189.54 |
Interest Expense | -19.47 | -16.92 | -5.31 | -3.5 | -6.54 |
Interest & Investment Income | - | 0.46 | 3.77 | 0.15 | 0.01 |
Earnings From Equity Investments | - | - | -7.68 | -4.18 | - |
Currency Exchange Gain (Loss) | - | -11.15 | -7.26 | -0.87 | -0.53 |
Other Non Operating Income (Expenses) | -3.16 | -23.61 | 12.21 | 1.04 | -1.92 |
EBT Excluding Unusual Items | -74.97 | -197.54 | -121.13 | 835.55 | 180.56 |
Impairment of Goodwill | - | - | - | -1.72 | - |
Gain (Loss) on Sale of Investments | - | - | -0 | 2.71 | 0.49 |
Gain (Loss) on Sale of Assets | - | -0.11 | 0.3 | 2.78 | - |
Asset Writedown | -6.73 | -84.57 | -21.19 | -0 | - |
Other Unusual Items | - | 2.35 | - | 23.51 | -0.38 |
Pretax Income | -81.7 | -252.8 | -142.03 | 862.83 | 180.67 |
Income Tax Expense | -0.86 | -0.94 | -1.32 | 157.26 | 48.1 |
Earnings From Continuing Operations | -80.84 | -251.85 | -140.71 | 705.57 | 132.57 |
Net Income to Company | -80.84 | -251.85 | -140.71 | 705.57 | 132.57 |
Minority Interest in Earnings | 12.06 | 53.71 | 45.26 | -447.48 | -113.19 |
Net Income | -68.78 | -198.15 | -95.45 | 258.09 | 19.39 |
Net Income to Common | -68.78 | -198.15 | -95.45 | 258.09 | 19.39 |
Net Income Growth | - | - | - | 1231.38% | -35.75% |
Shares Outstanding (Basic) | 983 | 968 | 963 | 963 | 965 |
Shares Outstanding (Diluted) | 983 | 968 | 963 | 963 | 965 |
Shares Change (YoY) | 1.45% | 0.55% | - | -0.15% | -0.39% |
EPS (Basic) | -0.07 | -0.20 | -0.10 | 0.27 | 0.02 |
EPS (Diluted) | -0.07 | -0.20 | -0.10 | 0.27 | 0.02 |
EPS Growth | - | - | - | 1233.42% | -35.49% |
Free Cash Flow | - | -203.54 | 132.31 | 374.58 | 28.29 |
Free Cash Flow Per Share | - | -0.21 | 0.14 | 0.39 | 0.03 |
Dividend Per Share | - | - | - | 0.010 | - |
Gross Margin | 10.51% | -7.01% | 16.19% | 59.46% | 57.40% |
Operating Margin | -71.19% | -207.51% | -55.13% | 45.52% | 30.39% |
Profit Margin | -93.57% | -281.02% | -45.02% | 13.94% | 3.11% |
Free Cash Flow Margin | - | -288.67% | 62.41% | 20.23% | 4.54% |
EBITDA | -38.12 | -132.11 | -72.16 | 898.62 | 244.95 |
EBITDA Margin | -51.86% | -187.36% | -34.04% | 48.53% | 39.27% |
D&A For EBITDA | 14.21 | 14.21 | 44.7 | 55.72 | 55.42 |
EBIT | -52.33 | -146.32 | -116.86 | 842.9 | 189.54 |
EBIT Margin | -71.19% | -207.51% | -55.13% | 45.52% | 30.39% |
Effective Tax Rate | - | - | - | 18.23% | 26.62% |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.